Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $44.10.

Several equities analysts have weighed in on CLDX shares. Canaccord Genuity Group reissued a “buy” rating and issued a $62.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Mizuho started coverage on shares of Celldex Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price objective on the stock. Finally, Barclays boosted their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a report on Wednesday, December 17th.

Insider Activity at Celldex Therapeutics

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of Celldex Therapeutics stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. The trade was a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL acquired a new stake in shares of Celldex Therapeutics during the third quarter worth about $818,000. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics during the 3rd quarter worth approximately $42,000. Advisory Services Network LLC bought a new position in Celldex Therapeutics in the third quarter valued at approximately $139,000. Verition Fund Management LLC lifted its stake in Celldex Therapeutics by 62.8% in the third quarter. Verition Fund Management LLC now owns 55,140 shares of the biopharmaceutical company’s stock valued at $1,426,000 after buying an additional 21,269 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its holdings in shares of Celldex Therapeutics by 5.9% in the third quarter. Polar Capital Holdings Plc now owns 1,300,436 shares of the biopharmaceutical company’s stock valued at $33,642,000 after buying an additional 72,001 shares during the period.

Celldex Therapeutics Stock Performance

NASDAQ CLDX opened at $26.28 on Wednesday. The stock has a market capitalization of $1.75 billion, a P/E ratio of -7.78 and a beta of 1.19. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $30.50. The stock has a fifty day moving average of $26.19 and a 200-day moving average of $24.63.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. Equities research analysts forecast that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.